KPRX KIORA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1372514 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-99.9%
TTM net income YoY-529.2%
TTM EPS YoY84.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-55,210.8%
Net margin-60,257.3%
FCF margin—
EBITDA margin-55,137.5%
Returns
ROE-41.1%
ROA-31.5%
ROIC (approx.)-74.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio5.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-11.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $16.02M |
| R&D expense | $10.78M | $7.84M |
| SG&A expense | $5.75M | $5.54M |
| Operating income | -$12.83M | $4.51M |
| Interest expense | $19,960 | $21,446 |
| Pretax income | -$12.12M | $5.66M |
| Income tax | -$1.28M | $2.07M |
| Net income | -$10.84M | $3.59M |
| EBITDA | -$12.81M | $4.53M |
| EPS (basic) | -2.60 | 0.93 |
| EPS (diluted) | -2.64 | 0.87 |
| Weighted avg. shares (diluted) | 4.10M | 4.13M |
| Balance sheet | ||
| Cash & equivalents | $8.70M | $3.80M |
| Short-term investments | $8.39M | $23.00M |
| Receivables | $1.52M | $601,197 |
| Current assets | $21.75M | $29.71M |
| PP&E, net | $91,672 | $5,232 |
| Intangibles | $2.06M | $6.69M |
| Total assets | $24.25M | $36.48M |
| Current liabilities | $3.63M | $6.01M |
| Total liabilities | $8.13M | $10.72M |
| Shareholders' equity | $16.13M | $25.76M |
| Shares outstanding | 3.76M | 3.00M |
| Cash flow statement | ||
| Operating cash flow | -$9.96M | $8.56M |
| Capital expenditure | $110,789 | $6,256 |
| Free cash flow | -$10.07M | $8.55M |
| Investing cash flow | $14.43M | -$22.66M |
| Financing cash flow | $265,655 | $15.50M |
| Depreciation & amortization | $24,801 | $19,205 |
| Stock-based compensation | $900,236 | $656,593 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.